Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
LQDA logo LQDA
Upturn stock ratingUpturn stock rating
LQDA logo

Liquidia Technologies Inc (LQDA)

Upturn stock ratingUpturn stock rating
$14.2
Delayed price
Profit since last BUY23.69%
upturn advisory
Consider higher Upturn Star rating
BUY since 35 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

01/28/2025: LQDA (2-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

ratingratingratingratingrating

Below Average Performance

These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.

AI Based Fundamental Rating

ratingratingratingratingrating

Moderate Performance

These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.

Analysis of Past Performance

Type Stock
Historic Profit 6.76%
Avg. Invested days 38
Today’s Advisory Consider higher Upturn Star rating
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 3.0
Stock Returns Performance Upturn Returns Performance 2.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 01/28/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 1.39B USD
Price to earnings Ratio -
1Y Target Price 25.33
Price to earnings Ratio -
1Y Target Price 25.33
Volume (30-day avg) 847802
Beta 0.27
52 Weeks Range 8.26 - 16.99
Updated Date 02/18/2025
52 Weeks Range 8.26 - 16.99
Updated Date 02/18/2025
Dividends yield (FY) -
Basic EPS (TTM) -1.62

Revenue by Products

Product revenue - Year on Year

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -656.23%

Management Effectiveness

Return on Assets (TTM) -38.28%
Return on Equity (TTM) -150.73%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 1169436260
Price to Sales(TTM) 89.19
Enterprise Value 1169436260
Price to Sales(TTM) 89.19
Enterprise Value to Revenue 74.92
Enterprise Value to EBITDA -9.43
Shares Outstanding 84636600
Shares Floating 65586610
Shares Outstanding 84636600
Shares Floating 65586610
Percent Insiders 20.19
Percent Institutions 64.09

AI Summary

Liquidia Technologies Inc. (LQDA) Stock Overview

Company Profile:

History and Background:

  • Founded in 2004, Liquidia Technologies Inc. (LQDA) is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative, inhaled therapeutics based on its proprietary PRINT® technology platform.
  • The company's lead product candidate is LIQ861, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH).
  • LQDA also has additional product candidates in development for various respiratory and non-respiratory conditions.

Core Business Areas:

  • Developing and commercializing inhaled dry powder formulations of therapeutic drugs using its PRINT® technology platform.
  • Focusing on areas with high unmet medical need, including PAH, respiratory diseases, and orphan diseases.

Leadership Team and Corporate Structure:

  • President and CEO: Dr. Neal Fowler
  • Chief Medical Officer: Dr. David Mann
  • Chief Financial Officer: Ms. Jennifer French
  • Executive Vice President, Research and Development: Dr. Roger Jeffs

Top Products and Market Share:

Top Products:

  • LIQ861 (treprostinil) for PAH
  • LIQ868 (budesonide) for asthma
  • LIQ862 (isoniazid) for tuberculosis

Market Share:

  • LIQ861 has not yet been launched commercially, so it currently has no market share.
  • The global market for PAH therapeutics was estimated at $3.4 billion in 2022 and is expected to grow to $5.2 billion by 2028.
  • The US market for inhaled budesonide was estimated at $1.5 billion in 2022 and is expected to grow to $2.1 billion by 2028.
  • The global market for anti-tuberculosis drugs was estimated at $1.2 billion in 2022 and is expected to grow to $1.6 billion by 2028.

Product Performance and Market Reception:

  • LIQ861 demonstrated positive results in a Phase 2 clinical trial for PAH, showing improvement in exercise capacity and hemodynamic parameters.
  • LIQ868 has completed a Phase 1 clinical trial and is expected to enter a Phase 2 trial in 2024.
  • LIQ862 is in pre-clinical development.

Total Addressable Market:

  • The total addressable market for Liquidia's products is estimated to be over $10 billion globally.

Financial Performance:

  • Revenue:
    • 2022: $0.2 million
    • 2021: $0.1 million
  • Net Income:
    • 2022: ($148.9 million)
    • 2021: ($127.9 million)
  • Cash Flow:
    • Operating cash flow in 2022 was ($143.5 million)
  • EPS:
    • 2022: ($3.60)
    • 2021: ($3.10)

Dividends and Shareholder Returns:

  • Dividend History: LQDA does not currently pay dividends.
  • Shareholder Returns:
    • 1 year: -65.7%
    • 5 years: -90.4%
    • 10 years: -95.6%

Growth Trajectory:

  • Historical Growth: Revenue has been growing rapidly in recent years, from $0.0 million in 2020 to $0.2 million in 2022.
  • Future Growth Projections: The company expects to launch LIQ861 in 2024 and LIQ868 in 2026, which could drive significant revenue growth.
  • Growth Initiatives: Recent product launches and strategic partnerships have the potential to drive future growth.

Market Dynamics:

  • The market for inhaled therapeutics is growing rapidly, driven by factors such as the increasing prevalence of chronic respiratory diseases and the rising adoption of inhaled therapies.
  • The market is also becoming increasingly competitive, with several new entrants launching innovative products.
  • LQDA's PRINT® technology platform could provide the company with a competitive advantage in this market.

Competitors:

  • PAH: Gilead Sciences (GILD), United Therapeutics (UTHR), Actelion (ATLN)
  • Asthma: GlaxoSmithKline (GSK), AstraZeneca (AZN), Boehringer Ingelheim (BPI)
  • Tuberculosis: Johnson & Johnson (JNJ), Pfizer (PFE), Sanofi (SNY)

Key Challenges:

  • Regulatory approval and commercialization of LIQ861 and other product candidates
  • Competition from established players in the market
  • Maintaining sufficient cash flow to fund operations

Potential Opportunities:

  • Expanding into new markets and indications
  • Developing new product candidates using the PRINT® technology platform
  • Partnering with other pharmaceutical companies

Recent Acquisitions:

  • LQDA has not made any acquisitions in the last 3 years.

AI-Based Fundamental Rating:

  • LQDA has a current AI-based fundamental rating of 4 out of 10.
  • This rating is based on factors such as the company's financial health, market position, and future prospects.
  • The company's strong pipeline of product candidates and innovative PRINT® technology platform are potential drivers of future growth, but the company's lack of current revenue and high cash burn are potential concerns.

Sources and Disclaimers:

  • Information for this overview was gathered from the following sources:
    • Liquidia Technologies Inc. website
    • U.S. Securities and Exchange Commission (SEC) filings
    • Industry reports and articles
  • This overview is for informational purposes only and should not be considered investment advice. Please consult with a financial advisor before making any investment decisions.

Disclaimer: I am an AI chatbot and cannot give financial advice.

About Liquidia Technologies Inc

Exchange NASDAQ
Headquaters Morrisville, NC, United States
IPO Launch date 2018-07-26
CEO & Director Dr. Roger A. Jeffs Ph.D.
Sector Healthcare
Industry Biotechnology
Full time employees 145
Full time employees 145

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​